The US Food and Drug Administration has approved Abbott Laboratories Inc.’s plan for the REPAIR MR trial to evaluate its MitraClip mitral valve repair system in “moderate-risk” patients who are eligible for surgery, the company announced on 13 January.
Abbott’s MitraClip, now in its fourth generation, is the only transcatheter mitral valve repair technology approved by the FDA